The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy

[1]  Shau-Hsuan Li,et al.  The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy , 2018, PloS one.

[2]  S. Tommasi,et al.  VEGF and TWIST1 in a 16‐biomarker immunoprofile useful for prognosis of breast cancer patients , 2017, International journal of cancer.

[3]  Shau-Hsuan Li,et al.  The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy , 2017, Oncotarget.

[4]  M. Bidziński,et al.  Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients , 2017, PloS one.

[5]  Zhi-hong Zheng,et al.  MAPK, NFκB, and VEGF signaling pathways regulate breast cancer liver metastasis , 2017, Oncotarget.

[6]  X. Ni,et al.  [Pathologic response and changes of serum VEGF during chemoradiotherapy may predict prognosis in non-surgical patients with esophageal carcinoma]. , 2016, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[7]  S. Motoyama,et al.  Novel Candidate Biomarkers of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma: A Systematic Review , 2016, European Surgical Research.

[8]  T. Chou,et al.  Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. , 2010, The Annals of thoracic surgery.

[9]  J. Ajani,et al.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Mengzhong Liu,et al.  [Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients--a report of 43 cases]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[11]  V. Gebski,et al.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. , 2005, The Lancet. Oncology.

[12]  Dingcai Cao,et al.  A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer , 2004, Clinical Cancer Research.

[13]  E. Anaissie,et al.  Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma , 2004, Clinical Cancer Research.

[14]  D. Neal,et al.  An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer , 2003, British Journal of Cancer.

[15]  E. Estey,et al.  Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes , 2002, Cancer.

[16]  D. Girling.  Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.

[17]  J. Schulte‐Mönting,et al.  Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  H. Matsubara,et al.  Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma , 2002, British Journal of Cancer.

[19]  H. Nielsen,et al.  Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma , 2002, British Journal of Cancer.

[20]  H. Matsubara,et al.  Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma , 2001, Cancer.

[21]  T. Yoshikawa,et al.  Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. , 2000, Cancer letters.

[22]  J. Ajani,et al.  Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. , 1998, The New England journal of medicine.

[23]  I. Hyodo,et al.  Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. , 1998, European journal of cancer.

[24]  D. Dhar,et al.  The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus , 1998, Cancer.

[25]  L. Ellis,et al.  Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. , 1998, European journal of cancer.

[26]  S. Akiba,et al.  Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. , 1996, Journal of the National Cancer Institute.

[27]  Y. Chung,et al.  Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[29]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[30]  F. Wong,et al.  REPUBLIC OF CHINA , 2002 .

[31]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[32]  K. Grankvist,et al.  Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. , 2000, The Journal of urology.

[33]  P. Vermeulen,et al.  Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. , 1997, British Journal of Cancer.